Is Cullinan Oncology LLC (CGEM) overvalued? · $830.3M cap
Cullinan Oncology LLC (CGEM) is a biotechnology company listed on US.
This page asks whether Cullinan Oncology LLC (CGEM) looks expensive on cached numbers — not a short thesis.
Latest reported CGEM revenue for 2022-12-31 was $0. Net income was $109.2M. CGEM currently screens at market cap $830.3M.
CGEM currently screens at market cap $830.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CGEM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CGEM stock page for the full model, not this heading.
Not investment advice.